Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURSUIT-Maintenance: Golimumab in Ulcerative Colitis
NCT00488631Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2007
- Primary completion
- Oct 2011
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of golimumab in ulcerative colitis (UC) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants in Clinical Response Through Week 54. Started Sep 2007; status: completed.
02
Drugs
golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00488631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00488631.